NOTCH4 and breast carcinoma: Activation of JAG1/Notch4 signalling was sufficient to induce endocrine therapy resistance in MCF-7 cells, and tamoxifen resistance could be predicted for in ER+ breast cancer patients using a Notch4/HES/Hey gene signature.